These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 30201212)

  • 1. Blood-brain barrier integrity in a mouse model of Alzheimer's disease with or without acute 3D6 immunotherapy.
    Gustafsson S; Gustavsson T; Roshanbin S; Hultqvist G; Hammarlund-Udenaes M; Sehlin D; Syvänen S
    Neuropharmacology; 2018 Dec; 143():1-9. PubMed ID: 30201212
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monitoring Blood-Brain Barrier Integrity Following Amyloid-β Immunotherapy Using Gadolinium-Enhanced MRI in a PDAPP Mouse Model.
    Blockx I; Einstein S; Guns PJ; Van Audekerke J; Guglielmetti C; Zago W; Roose D; Verhoye M; Van der Linden A; Bard F
    J Alzheimers Dis; 2016 Sep; 54(2):723-35. PubMed ID: 27567811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High detection sensitivity with antibody-based PET radioligand for amyloid beta in brain.
    Fang XT; Hultqvist G; Meier SR; Antoni G; Sehlin D; Syvänen S
    Neuroimage; 2019 Jan; 184():881-888. PubMed ID: 30300753
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ABCG2 is upregulated in Alzheimer's brain with cerebral amyloid angiopathy and may act as a gatekeeper at the blood-brain barrier for Abeta(1-40) peptides.
    Xiong H; Callaghan D; Jones A; Bai J; Rasquinha I; Smith C; Pei K; Walker D; Lue LF; Stanimirovic D; Zhang W
    J Neurosci; 2009 Apr; 29(17):5463-75. PubMed ID: 19403814
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vascular alterations in PDAPP mice after anti-Aβ immunotherapy: Implications for amyloid-related imaging abnormalities.
    Zago W; Schroeter S; Guido T; Khan K; Seubert P; Yednock T; Schenk D; Gregg KM; Games D; Bard F; Kinney GG
    Alzheimers Dement; 2013 Oct; 9(5 Suppl):S105-15. PubMed ID: 23583235
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amyloid-β contributes to blood-brain barrier leakage in transgenic human amyloid precursor protein mice and in humans with cerebral amyloid angiopathy.
    Hartz AM; Bauer B; Soldner EL; Wolf A; Boy S; Backhaus R; Mihaljevic I; Bogdahn U; Klünemann HH; Schuierer G; Schlachetzki F
    Stroke; 2012 Feb; 43(2):514-23. PubMed ID: 22116809
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting isoaspartate-modified Aβ rescues behavioral deficits in transgenic mice with Alzheimer's disease-like pathology.
    Gnoth K; Piechotta A; Kleinschmidt M; Konrath S; Schenk M; Taudte N; Ramsbeck D; Rieckmann V; Geissler S; Eichentopf R; Barendrecht S; Hartlage-Rübsamen M; Demuth HU; Roßner S; Cynis H; Rahfeld JU; Schilling S
    Alzheimers Res Ther; 2020 Nov; 12(1):149. PubMed ID: 33189132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of Hit Compounds Identified from High-throughput Screening for their Effect on Blood-brain Barrier Integrity and Amyloid-β Clearance: In Vitro and In Vivo Studies.
    Elfakhri KH; Duong QV; Langley C; Depaula A; Mousa YM; Lebeouf T; Cain C; Kaddoumi A
    Neuroscience; 2018 May; 379():269-280. PubMed ID: 29596966
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Permeability of proteins at the blood-brain barrier in the normal adult mouse and double transgenic mouse model of Alzheimer's disease.
    Poduslo JF; Curran GL; Wengenack TM; Malester B; Duff K
    Neurobiol Dis; 2001 Aug; 8(4):555-67. PubMed ID: 11493021
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Method for measurement of the blood-brain barrier permeability in the perfused mouse brain: application to amyloid-beta peptide in wild type and Alzheimer's Tg2576 mice.
    LaRue B; Hogg E; Sagare A; Jovanovic S; Maness L; Maurer C; Deane R; Zlokovic BV
    J Neurosci Methods; 2004 Sep; 138(1-2):233-42. PubMed ID: 15325132
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduced Efficacy of Anti-Aβ Immunotherapy in a Mouse Model of Amyloid Deposition and Vascular Cognitive Impairment Comorbidity.
    Weekman EM; Sudduth TL; Caverly CN; Kopper TJ; Phillips OW; Powell DK; Wilcock DM
    J Neurosci; 2016 Sep; 36(38):9896-907. PubMed ID: 27656027
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IgG-assisted age-dependent clearance of Alzheimer's amyloid beta peptide by the blood-brain barrier neonatal Fc receptor.
    Deane R; Sagare A; Hamm K; Parisi M; LaRue B; Guo H; Wu Z; Holtzman DM; Zlokovic BV
    J Neurosci; 2005 Dec; 25(50):11495-503. PubMed ID: 16354907
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of ADAM10 promotes the clearance of Aβ across the BBB by reducing LRP1 ectodomain shedding.
    Shackleton B; Crawford F; Bachmeier C
    Fluids Barriers CNS; 2016 Aug; 13(1):14. PubMed ID: 27503326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brain Penetrating Bifunctional Erythropoietin-Transferrin Receptor Antibody Fusion Protein for Alzheimer's Disease.
    Chang R; Al Maghribi A; Vanderpoel V; Vasilevko V; Cribbs DH; Boado R; Pardridge WM; Sumbria RK
    Mol Pharm; 2018 Nov; 15(11):4963-4973. PubMed ID: 30252487
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blood-Brain Barrier Disruption Increases Amyloid-Related Pathology in TgSwDI Mice.
    Abdallah IM; Al-Shami KM; Yang E; Kaddoumi A
    Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33513818
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy reduces vascular amyloid-beta in PDAPP mice.
    Schroeter S; Khan K; Barbour R; Doan M; Chen M; Guido T; Gill D; Basi G; Schenk D; Seubert P; Games D
    J Neurosci; 2008 Jul; 28(27):6787-93. PubMed ID: 18596154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ADAMTS13 maintains cerebrovascular integrity to ameliorate Alzheimer-like pathology.
    Cao Y; Xu H; Zhu Y; Shi MJ; Wei L; Zhang J; Cheng S; Shi Y; Tong H; Kang L; Lu L; Luo H; Yang X; Bai X; Wang R; Ma Y; Wang Y; Wang Z; Zhong K; Zhao BQ; Fan W
    PLoS Biol; 2019 Jun; 17(6):e3000313. PubMed ID: 31185010
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blood-Brain Barrier Penetrating Biologic TNF-α Inhibitor for Alzheimer's Disease.
    Chang R; Knox J; Chang J; Derbedrossian A; Vasilevko V; Cribbs D; Boado RJ; Pardridge WM; Sumbria RK
    Mol Pharm; 2017 Jul; 14(7):2340-2349. PubMed ID: 28514851
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SAR228810: an antibody for protofibrillar amyloid β peptide designed to reduce the risk of amyloid-related imaging abnormalities (ARIA).
    Pradier L; Blanchard-Brégeon V; Bohme A; Debeir T; Menager J; Benoit P; Barneoud P; Taupin V; Bertrand P; Dugay P; Cameron B; Shi Y; Naimi S; Duchesne M; Gagnaire M; Weeden T; Travaline T; Reczek D; Khiroug L; Slaoui M; Brunel P; Fukuyama H; Ravetch J; Canton T; Cohen C
    Alzheimers Res Ther; 2018 Nov; 10(1):117. PubMed ID: 30486882
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta.
    Racke MM; Boone LI; Hepburn DL; Parsadainian M; Bryan MT; Ness DK; Piroozi KS; Jordan WH; Brown DD; Hoffman WP; Holtzman DM; Bales KR; Gitter BD; May PC; Paul SM; DeMattos RB
    J Neurosci; 2005 Jan; 25(3):629-36. PubMed ID: 15659599
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.